Informations cliniques
Les tiques peuvent transmettre divers agents infectieux viraux, bactériens et parasitaires à l’homme lorsqu’elles se nourrissent de sang. Outre Borrelia, responsable de la borréliose de Lyme, la maladie transmise par les tiques la plus fréquente dans l’hémisphère nord, l’éventail des agents pathogènes comprend le virus de l’encéphalite à tiques, le virus de la fièvre de Crimée-Congo, Anaplasma, Rickettsia, Babesia, Ehrlichia et Coxiella. Les infections transmises par les tiques peuvent, en fonction de l’agent pathogène, entraîner une multitude de symptômes cliniques, notamment au niveau de la peau, des articulations, des muscles, des organes internes et du système nerveux central. Des infections asymptomatiques ou subcliniques sont possibles, tout comme des évolutions graves mettant la vie en danger. Comme il n’existe que des vaccins pour certains des agents pathogènes transmis par les tiques, la prophylaxie de l’exposition est la protection la plus efficace.
Diagnostic
Le diagnostic de laboratoire des infections transmises par les tiques repose sur des méthodes de détection directes et indirectes. Les méthodes directes comprennent par exemple les étalements sanguins, les cultures d’agents pathogènes ou les tests basés sur la PCR, tandis que la détection indirecte repose généralement sur la détermination d’anticorps spécifiques dirigés contre l’agent infectieux concerné dans le sérum, le plasma ou le liquide céphalorachidien du patient. Dans les cas où il est difficile d’obtenir un échantillon approprié pour la détection directe de l’agent pathogène ou lorsque la quantité d’agent pathogène qu’il contient est trop faible, la détection des anticorps constitue souvent la principale méthode de diagnostic de laboratoire. EUROIMMUN propose une large gamme de systèmes de tests sérologiques, notamment des ELISA, des ChLIA, des tests d’immunofluorescence (IFI), des immunoblots et des EUROMicroblots, des immunoblots miniaturisés en format microplaque.
| Technology | Parameter | Substrate | Species | Calibration | Ig Class | Format | Order No. |
|---|---|---|---|---|---|---|---|
| ELISA |
Anti-TBE Virus CSF ELISA 2.0 (IgG) tick-borne encephalitis virus |
antigen-coated microplate wells |
TBE viral proteins | 5/25/50/100/175/230 U/ml | IgG |
96 x 01 |
EI 2661-9601-2L G |
| ELISA |
Anti-TBE Virus CSF ELISA 2.0 (IgM) tick-borne encephalitis virus |
antigen-coated microplate wells |
TBE viral proteins | IgM |
96 x 01 |
EI 2661-9601-2L M | |
| ELISA |
CSQ pair of controls anti-Borrelia (IgG) |
IgG |
02 x 20 |
CK 2132-0220-L G | |||
| ELISA | Anti-Borrelia CSF ELISA 2.0 (IgM) |
antigen-coated microplate wells |
TBE viral proteins | IgM |
96 x 01 |
EI 2132-9601-2L M | |
| ELISA |
CSF: Anti-Borrelia plus VlsE ELISA (IgG) Sample type: CSF/serum pair |
antigen-coated microplate wells |
whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii PLUS recombinant VlsE from Borrelia burgdorferi sensu stricto |
5/25/50/100/175/230 U | IgG |
96 x 01 |
EI 2132-9601-L G |
| EUROLINE |
Anti-Borrelia EUROLINE-RN-AT (IgG) (p18, p19, p20, p21, p58, OspC (p25), p39, p83, LBb, LBa, VlsE Bg, VlsE Bb, VlsE Ba separately) |
EUROLINE | IgG IgG IgG |
240 x 01 32 x 01 50 x 01 |
DN 2131-24001 G DN 2131-3201 G DN 2131-5001 G |
||
| EUROLINE |
Anti-Borrelia EUROLINE-RN-AT (IgM) (OspC Bg native, OspC Bb native, OspC Ba native, p39, VlsE Bb separately) |
EUROLINE | IgM IgM IgM |
240 x 01 32 x 01 50 x 01 |
DN 2131-24001 M DN 2131-3201 M DN 2131-5001 M |
||
| ELISA | Anti-Crimean-Congo fever virus(CCHFV) ELISA (IgG) |
antigen-coated microplate wells |
recombinant protein from CCHFV |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 279a-9601 G |
| ELISA | Anti-Crimean-Congo fever virus(CCHFV) ELISA (IgM) |
antigen-coated microplate wells |
recombinant protein from CCHFV |
semi-quantitative | IgM |
96 x 01 |
EI 279a-9601 M |
| IIFT | TBE virus (TBEV) |
infected and non- infected cells (2 BIOCHIPs per field) |
EU 14 | IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 |
FI 2661-1005 G FI 2661-1005 M FI 2661-1010 G FI 2661-1010 M |
|
| IIFT |
Flavivirus Mosaic 1 TBE virus (TBEV) West Nile virus (WNV) Japanese encephalitis virus (JEV) Yellow fever virus (YFV) |
4 BIOCHIPs per field: infected cells infected cells infected cells infected cells |
EU 14 EU 14 EU 14 EU 14 |
IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 |
FI 2661-1005-1 G FI 2661-1005-1 M FI 2661-1010-1 G FI 2661-1010-1 M |
|
| IIFT |
Flavivirus Profile 2 upper row: TBE virus (TBEV) West Nile virus (WNV) Japanese encephalitis virus (JEV) Yellow fever virus (YFV) bottom row: Dengue virus types 1 - 4 (DENV) |
infected cells infected cells infected cells infected cells infected cells |
EU 14 EU 14 EU 14 EU 14 EU 14 |
IgG IgM IgG IgM |
10 x 05 10 x 05 20 x 05 20 x 05 |
FI 2661-1005-2 G FI 2661-1005-2 M FI 2661-2005-2 G FI 2661-2005-2 M |
|
| ELISA |
Anti-TBE Virus ELISA 2.0 (IgG) tick-borne encephalitis virus |
antigen-coated microplate wells |
TBE viral proteins | IgG |
96 x 01 |
EI 2661-9601-2 G | |
| ELISA |
Anti-TBE Virus ELISA 2.0 (IgM) tick-borne encephalitis virus |
antigen-coated microplate wells |
semi-quantitative | IgM |
96 x 01 |
EI 2661-9601-2 M | |
| IIFT |
EUROPLUS Borrelia afzelii Borrelia burgdorferi (USA) OspC antigen VlsE antigen |
4 BIOCHIPs per field: bacterial smear bacterial smear OspC BIOCHIPs VlsE BIOCHIPs |
B. afzelii B. burgd. (USA) B. burgdorferi recombinant |
IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 |
FI 2136-1005-1 G FI 2136-1005-1 M FI 2136-1010-1 G FI 2136-1010-1 M |
|
| ELISA |
Anti-Borrelia ELISA (IgM) whole antigen extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii |
antigen-coated microplate wells |
whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii |
2/20/200 RU/ml | IgM |
96 x 01 |
EI 2132-9601 M |
| ELISA |
Anti-Borrelia plus VlsE ELISA (IgG) whole antigen extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii plus recombinant VlsE |
antigen-coated microplate wells |
whole antigen, detergent extracts of Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii plus recombinant VlsE from Borrelia burgdorferi sensu stricto |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2132-9601-2 G |
| ELISA | Anti-Coxiella burnetii Phase 1 ELISA (IgG) |
antigen-coated microplate wells |
native antigens from Coxiella burnetii cells in the chronical phase |
semi-quantitative | IgG |
96 x 01 |
EI 217a-9601-1 G |
| ELISA | Anti-Coxiella burnetii Phase 2 ELISA (IgG) |
antigen-coated microplate wells |
native antigens from Coxiella burnetii cells in the acute phase |
semi-quantitative | IgG |
96 x 01 |
EI 217a-9601-2 G |
| ELISA | Anti-Coxiella burnetii Phase 2 ELISA (IgM) |
antigen-coated microplate wells |
native antigens from Coxiella burnetii cells in the acute phase |
semi-quantitative | IgM |
96 x 01 |
EI 217a-9601-2 M |
| EUROLINE |
positive control serum: IgG, human, 50x concentrated for Borrelia |
IgG |
05 x 07 |
CL 2131-0507 G | |||
| EUROLINE |
positive control serum: IgM, human, 50x concentrated for Borrelia |
IgM |
05 x 07 |
CL 2131-0507 M | |||
| EUROLINE |
Anti-Borrelia EUROLINE-RN-AT-adv (IgM) (OspC-adv Bsp, OspC-adv Bg, OspC-adv Bb, OspC-adv Ba, p39, VlsE Bb separately) |
EUROLINE | IgM IgM IgM |
240 x 01 32 x 01 50 x 01 |
DN 2131-24001-2 M DN 2131-3201-2 M DN 2131-5001-2 M |
||
| WESTERNBLOT |
antibodies against Borrelia afzelii IgG positive control (Westernblot/EUROLINE-WB) |
IgG |
50 x 05 |
CW 2131-5005 G | |||
| WESTERNBLOT |
antibodies against Borrelia afzelii IgM positive control (Westernblot/EUROLINE-WB) |
IgM |
50 x 05 |
CW 2131-5005 M | |||
| WESTERNBLOT |
antibodies against Borrelia burgdorferi IgG positive control |
IgG |
50 x 05 |
CW 2132-5005 G | |||
| WESTERNBLOT |
antibodies against Borrelia burgdorferi IgM positive control |
IgM |
50 x 05 |
CW 2132-5005 M | |||
| WESTERNBLOT |
antibodies against Borrelia garinii IgG positive control |
IgG |
50 x 05 |
CW 2134-5005 G | |||
| WESTERNBLOT |
antibodies against Borrelia garinii IgM positive control |
IgM |
50 x 05 |
CW 2134-5005 M | |||
| WESTERNBLOT | Anti-Borrelia EUROLINE-WB (IgG) | Westernblot |
whole antigen, SDS extract of Borrelia afzelii plus VlsE |
IgG IgG IgG IgG |
16 x 01 240 x 01 30 x 01 48 x 01 |
DY 2131-1601-1 G DY 2131-24001-1 G DY 2131-3001-1 G DY 2131-4801-1 G |
|
| WESTERNBLOT | Anti-Borrelia EUROLINE-WB (IgM) | Westernblot |
whole antigen, SDS extract of Borrelia afzelii plus VlsE |
IgM IgM IgM IgM |
16 x 01 240 x 01 30 x 01 48 x 01 |
DY 2131-1601-1 M DY 2131-24001-1 M DY 2131-3001-1 M DY 2131-4801-1 M |
|
| WESTERNBLOT | Anti-Borrelia afzelii-WESTERNBLOT (IgG) | Westernblot |
whole antigen, SDS extract of Borrelia afzelii |
IgG IgG |
240 x 01 30 x 01 |
DY 2131-24001 G DY 2131-3001 G |
|
| WESTERNBLOT | Anti-Borrelia afzelii-WESTERNBLOT (IgM) | Westernblot |
whole antigen, SDS extract of Borrelia afzelii |
IgM IgM |
240 x 01 30 x 01 |
DY 2131-24001 M DY 2131-3001 M |
|
| WESTERNBLOT | Anti-Borrelia burgdorferi-WESTERNBLOT (IgG) | Westernblot |
whole antigen, SDS extract of Borrelia burgdorferi sensu stricto |
IgG |
30 x 01 |
DY 2132-3001 G | |
| WESTERNBLOT | Anti-Borrelia burgdorferi-WESTERNBLOT (IgM) | Westernblot |
whole antigen, SDS extract of Borrelia burgdorferi sensu stricto |
IgM |
30 x 01 |
DY 2132-3001 M | |
| WESTERNBLOT | Anti-Borrelia garinii-WESTERNBLOT (IgG) | Westernblot |
whole antigen, SDS extract of Borrelia garinii |
IgG |
30 x 01 |
DY 2134-3001 G | |
| WESTERNBLOT | Anti-Borrelia garinii-WESTERNBLOT (IgM) | Westernblot |
whole antigen, SDS extract of Borrelia garinii |
IgM |
30 x 01 |
DY 2134-3001 M | |
| ChLIA | IDS Borrelia IgG | antigenic coated magnetic particles | Borrelia burgdorferi VlsE antigen |
semi-quantitative |
100 x 01 |
IS-ID62011 | |
| ChLIA | IDS Borrelia IgM | antigenic coated magnetic particles | B. afzelii, B. burgdorferi, B. garinii, B. spielmani OspC and B. burgdorferi VlsE antigen |
semi-quantitative |
100 x 01 |
IS-ID62021 | |
| ChLIA | IDS Borrelia Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID62301 | ||
| ChLIA | Anti-Borrelia ChLIA (IgG) | Antigen-coated magnetic particles |
recombinant VlsE, recombinant DbpA |
quantitative | IgG |
100 x 1 |
LI 2132-10010 G |
| ChLIA | Anti-Borrelia ChLIA (IgM) | Antigen-coated magnetic particles | recombinant OspC | quantitative | IgM |
100 x 1 |
LI 2132-10010 M |
| ChLIA | Control set Anti-Borrelia ChLIA (IgG) | 2 x 0.5 ml control 1/2 | IgG |
02 x 02 |
LR 2132-20210 G | ||
| ChLIA | Control set Anti-Borrelia ChLIA (IgM) | 2 x 0.5 ml control 1/2 | IgM |
02 x 02 |
LR 2132-20210 M | ||
| MICROBLOT | EUROMicroblot Anti Borrelia (IgG) | IgG |
96 x 01 |
KN 2131-9601 G | |||
| MICROBLOT | EUROMicroblot Anti Borrelia (IgM) | IgM |
96 x 01 |
KN 2131-9601 M | |||
|
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC. 1 Product manufactured by third party. Please contact your local Euroimmun representative for more information. | |||||||